2019
Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients
Menter A, Cordoro KM, Davis DMR, Kroshinsky D, Paller AS, Armstrong AW, Connor C, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kivelevitch D, Korman NJ, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Parra SL, Pathy AL, Farley Prater E, Rupani RN, Siegel M, Stoff B, Strober BE, Wong EB, Wu JJ, Hariharan V, Elmets CA. Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. Journal Of The American Academy Of Dermatology 2019, 82: 161-201. PMID: 31703821, DOI: 10.1016/j.jaad.2019.08.049.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdrenal Cortex HormonesAnthralinBiological ProductsCalcineurin InhibitorsCardiovascular DiseasesChildChild, PreschoolCoal TarComorbidityCyclosporineDermatologic AgentsDyslipidemiasEvidence-Based MedicineHumansInfantInfant, NewbornInflammatory Bowel DiseasesInsulin ResistanceMental HealthMetabolic SyndromeMethotrexateNicotinic AcidsObesityPhotochemotherapyPsoriasisRetinoidsConceptsPediatric patientsDermatology–National Psoriasis Foundation guidelinesTreatment of psoriasisImportant clinical questionsEvidence-based recommendationsJoint American AcademyPsoriasis managementInflammatory diseasesFoundation guidelinesClinical questionsPatientsAmerican AcademyPsoriasisProvider interactionsGuideline sectionsUnique physiologyGuidelinesPharmacokineticsDiseaseCareMultisystemHidradenitis suppurativa Epidemiology, clinical presentation, and pathogenesis
Goldburg S, Strober B, Payette M. Hidradenitis suppurativa Epidemiology, clinical presentation, and pathogenesis. Journal Of The American Academy Of Dermatology 2019, 82: 1045-1058. PMID: 31604104, DOI: 10.1016/j.jaad.2019.08.090.Peer-Reviewed Original ResearchConceptsClinical presentationPilosebaceous-apocrine unitPathogenesis of HSRole of cytokinesMedical education seriesQuality of lifeSinus tractPerianal areaInflammatory cytokinesInflammatory disordersHS pathogenesisFollicular hyperkeratosisInguinal areaLesion formationSubmammary foldPathogenesisCytokinesEducation seriesEpidemiologyPresentationRecent understandingPathogenic microorganismsSuppurativaAbscessPainJoint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities
Elmets CA, Leonardi CL, Davis DMR, Gelfand JM, Lichten J, Mehta NN, Armstrong AW, Connor C, Cordoro KM, Elewski BE, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kivelevitch D, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Lim HW, Paller AS, Parra SL, Pathy AL, Prater EF, Rupani R, Siegel M, Stoff B, Strober BE, Wong EB, Wu JJ, Hariharan V, Menter A. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. Journal Of The American Academy Of Dermatology 2019, 80: 1073-1113. PMID: 30772097, DOI: 10.1016/j.jaad.2018.11.058.Peer-Reviewed Original ResearchMeSH KeywordsArthritis, PsoriaticCardiovascular DiseasesComorbidityDyslipidemiasEvidence-Based MedicineHumansHypertensionInflammatory Bowel DiseasesKidney DiseasesLife StyleLiver DiseasesLung Diseases, ObstructiveMental HealthMetabolic SyndromeNeoplasmsObesityPatient Education as TopicPhysician's RolePsoriasisQuality of LifeSleep Apnea Syndromes
2017
Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR)
Strober B, Gooderham M, de Jong EMGJ, Kimball AB, Langley RG, Lakdawala N, Goyal K, Lawson F, Langholff W, Hopkins L, Fakharzadeh S, Srivastava B, Menter A. Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR). Journal Of The American Academy Of Dermatology 2017, 78: 70-80. PMID: 29102053, DOI: 10.1016/j.jaad.2017.08.051.Peer-Reviewed Original ResearchConceptsImpact of treatmentPsoriasis Longitudinal AssessmentConventional therapyAdverse eventsDepressive symptomsIncidence rateLongitudinal assessmentConventional systemic therapiesSevere psoriasisBiologic therapySystemic therapyLower incidenceStudy populationPatientsTherapySymptomsPsoriasisRegistryBiologicsPhototherapyDepressionIncidenceMultivariate modelingRiskTreatmentCharacterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry
Strober B, Karki C, Mason M, Guo N, Holmgren S, Greenberg J, Lebwohl M. Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry. Journal Of The American Academy Of Dermatology 2017, 78: 323-332. PMID: 29051036, DOI: 10.1016/j.jaad.2017.10.012.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnti-Inflammatory Agents, Non-SteroidalBiological ProductsBody Surface AreaComorbidityCost of IllnessCross-Sectional StudiesFatigueFemaleHumansInterleukin-12Interleukin-17Interleukin-23MaleMiddle AgedPainPatient Reported Outcome MeasuresProspective StudiesPsoriasisQuality of LifeRegistriesSeverity of Illness IndexThalidomideTumor Necrosis Factor-alphaUnited StatesConceptsCorrona Psoriasis RegistryPsoriasis RegistryDisease durationComparative safetyBody surface area involvementTumor necrosis factor inhibitorsIL-12/23 inhibitorsInterleukin-17A inhibitorInvestigator's Global AssessmentNecrosis factor inhibitorsSurface area involvementLonger disease durationCross-sectional studyLong-term safetyEfficacy of treatmentPsoriatic arthritis diagnosisQuality of lifeEfficacy of foodMultiple comorbiditiesRegistry cohortSystemic medicationsSystemic therapyFactor inhibitorsArea involvementBiologic treatment
2016
Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis
Wu J, Strober B, Hansen P, Ahlehoff O, Egeberg A, Qureshi A, Robertson D, Valdez H, Tan H, Wolk R. Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis. Journal Of The American Academy Of Dermatology 2016, 75: 897-905. PMID: 27498960, DOI: 10.1016/j.jaad.2016.06.012.Peer-Reviewed Original ResearchMeSH KeywordsAdultBlood PressureCardiovascular DiseasesCholesterolClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicComorbidityC-Reactive ProteinDyslipidemiasFemaleGlycated HemoglobinHumansMaleMetabolic SyndromeMiddle AgedPiperidinesProtein Kinase InhibitorsPsoriasisPyrimidinesPyrrolesRisk FactorsTreatment OutcomeTriglyceridesConceptsMajor adverse CV eventsCV risk factorsTotal/HDL cholesterol ratioEffects of tofacitinibHDL cholesterol ratioIncidence rateLow-density lipoproteinRisk factorsPlaque psoriasisCholesterol ratioLong-term extension dataC-reactive protein levelsHigh-density lipoprotein cholesterolAdverse CV eventsCardiovascular risk factorsSystemic inflammatory conditionsDose-dependent increaseCV eventsTofacitinib dosesCardiovascular outcomesLipoprotein cholesterolBlood pressureTofacitinib treatmentTotal cholesterolHemoglobin levels
2014
Accumulating Evidence for the Association and Shared Pathogenic Mechanisms Between Psoriasis and Cardiovascular-related Comorbidities
Shlyankevich J, Mehta N, Krueger J, Strober B, Gudjonsson J, Qureshi A, Tebbey P, Kimball A. Accumulating Evidence for the Association and Shared Pathogenic Mechanisms Between Psoriasis and Cardiovascular-related Comorbidities. The American Journal Of Medicine 2014, 127: 1148-1153. PMID: 25149424, PMCID: PMC4259841, DOI: 10.1016/j.amjmed.2014.08.008.Peer-Reviewed Original Research
2009
A series of critically challenging case scenarios in moderate to severe psoriasis: A Delphi consensus approach
Strober B, Berger E, Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb A, Horn EJ, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Menter A, Schwartzman S, Sobell JM, Young M. A series of critically challenging case scenarios in moderate to severe psoriasis: A Delphi consensus approach. Journal Of The American Academy Of Dermatology 2009, 61: s1-s46. PMID: 19527820, DOI: 10.1016/j.jaad.2009.03.017.Peer-Reviewed Original ResearchConceptsTreatment optionsSevere psoriasisAvailable evidence-based dataHistory of malignancyEfficacious treatment optionBreast-feeding womenMedical treatment optionsSystemic psoriasis therapiesEvidence-based dataDelphi consensus approachLatent tuberculosisPsoriatic diseaseLiver diseasePsoriasis therapyHealthy patientsTreatment recommendationsClinical trialsCardiovascular diseaseConsensus panelViral infectionPatientsOptimum managementDisease statesMedical evidenceDisease